WHO Pharmaceuticals Newsletter 1999, No. 01&02
(1999; 16 pages)
Table of Contents
Open this folder and view contentsRegulatory actions
Open this folder and view contentsDrug surveillance
Open this folder and view contentsNew developments
Open this folder and view contentsGeneral information
Close this folderMedication errors
View the documentDecimal dosages: confusion: USA
View the documentEltroxin (levothyroxine sodium): confusion in formulations: Ireland
View the documentPegaspargase (Oncaspar): misleading graphics: USA
View the documentRemeron (mirtazepine): strength confusion: USA
View the documentTiagabine and tizanidine: name confusion and similar dosing and tablet strength: USA
View the documentWarfarin (Coumadin): confusing instructions: USA
Open this folder and view contentsVeterinary medicine
 

Eltroxin (levothyroxine sodium): confusion in formulations: Ireland

Ireland. Since 1997, the Irish Medicines Board has received reports of three patients undergoing long-term thyroid replacement therapy who inadvertently received 50 microgram tablets in place of 100 microgram tablets, in one case leading to the development of fetal hypothyroidism.

While both tablets are white, the 100 microgram tablet is heavier and larger than the 50 microgram tablet and the name and strength is engraved on each tablet. In view of the potentially serious implications of the patient receiving the wrong strength, prescribers and pharmacists are reminded to advise patients to check their tablets, particularly if two strengths are dispensed.

Reference: Irish Medicines Board, Drug Safety Newsletter No. 8, September 1998.

to previous section to next section
 

Last updated: May 3, 2013